Spotlight

NOMINATIONS for the 2015 UCL Awards for Enterprise are now open!

Deadline: 5pm, Fri 20th Feb 2015
NOMINATE NOW

UCL Enterprise asks all UCL students and staff to help in honouring UCL’s enterprise activities by putting forth nominations for the 2015 Awards for Enterprise.



follow us on twitter


News

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launch today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona. More...

Six new approaches to fighting neurodegeneration to be funded in SBC's OI challenge

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is delighted to announce that UCL was one of the six exciting academic research projects to have been selected for support under its open innovation challenge in neurodegenerative disease. More...

Citrus Saturday raises £2500 for expansion in Swaziland

Citrus Saturday, UCL Advances’ initiative to encourage young people to consider entrepreneurship as a career option, has raised over £2500 through Indiegogo, the crowd-funding platform, to expand its reach in Swaziland. More...

KTP funding success: The Bartlett School of Construction and Project Management collaborates with AECOM on market forecasting

The Bartlett School of Construction and Project Management has secured a three-year Knowledge Transfer Partnership with AECOM Professional Services LLP to develop a suite of innovative market forecasting tools. More...

First patient dosed in trial of novel T-cell therapy for leukaemia Milestone for Cell Therapy Catapult, UCL Business & Imperial Innovations partnership

The first acute myeloid leukaemia patient has been dosed in a Phase I/ll cell therapy trial1 being undertaken by Catapult Therapy TCR Ltd, a partnership established in July 2014 to accelerate development of a novel T cell receptor (TCR) therapy. The trial is expected to involve five centres in the UK, and is to assess the safety and efficacy of the therapy, which targets diseases associated with overexpression of the WT1 antigen. Catapult Therapy TCR Ltd is an innovative partnership between the Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, UCL Business (UCLB) and Imperial Innovations. More...

Search UCL News